Keratin fragments as a serological indicator in patients with a liver disease

Czech version

Authors: J. Lata ¹; H. Mrlianová ²; O. Stibůrek ²; J. Nožička ³; Z. Čermáková ⁴; J. Gottwaldová ⁴; P. Drozd ⁵
Authors‘ workplace: Interní klinika Lékařské fakulty Ostravské Univerzity a FN Ostrava, přednosta doc. MUDr. Arnošt Martínek, CSc. ¹; Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Aleš Hep, CSc. ²; Histologická laboratoř Ústí nad Orlicí, přednosta primář MUDr. Jan Nožička, Ph. D. ³; Oddělení klinické biochemie FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Milan Dastych, CSc., MBA ⁴; Katedra biologie a ekologie Přírodovědecké fakulty Ostravské univerzity v Ostravě, vedoucí katedry Mgr. Pavel Drozd, Ph. D. ⁵
Published in: Vnitř Lék 2011; 57(12): 1025-1028
Category: 70th birthday of prof. MUDr. Petr Dítě, DrSc.

Overview

Introduction:
Determination of M30 antigen appears to be a sensitive method for evaluation of hepatocyte apoptosis. The aim of the present project was to implement this technique, compare M30 values in patients with a liver disease and healthy controls and to identify potential relationships between M30 values and other parameters.

Methods:
M30 antigen was assessed in 25 patients with a liver disease and 30 healthy controls. These results were compared between patients with a liver disease and the controls and correlated to a range of clinical and laboratory values, including tissue polypeptide-specific antigen (TPS), in patients with a liver disease.

Results:
We found significant differences in M30 values between controls and patients with a liver disease. The only significant correlations were the correlation between M30 and ALT, highly significant correlation between M30 and AST and highly significant correlation between M30 and TPS.

Conclusion:
The M30 antigen is a sensitive indicator of liver damage. Considering the highly significant correlation with TPS, it can be assumed that in some liver diseases, TPS could serve as a clinically useful indicator of apoptosis.

Key words:
liver disease – M30 antigen – tissue polypeptide-specific antigen (TPS) – keratin fragments – hepatocyte apoptosis

Sources

1. R Development Core Team (2011). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna: Austria 2011. www.R-project.org.

2. Hůlek P, Dresslerová I. Steatóza a steatohepatitida u diabetika. Vnitř Lék 2011; 57: 364–367.

3. Brůha R. Nealkoholová steatóza a steatohepatitida. Vnitř Lék 2010; 56: 173–175.

4. Naveau S, Gaudé G, Asnacios A et al. Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.

5. Tajmer P. Fibróza jater. In: Špičák J (ed.). Novinky v gastroenterologii a hepatologii. 1. vyd. Praha: Grada 2008: 35–46.

6. Moll R, Franke WW, Schiller DL et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11–24.

7. Fuchs E, Tyner AL, Guidice G et al. The human keratin genes and their differential expression. In: Sawyer RH (ed.). The Molecular and Developmental Biology of Keratins. New York: Academic Press 1987: 5–34.

8. Sundström BE, D’Amico Y, Brundell J. Development of a new Profiligen TPA IRMA assay using monoclonal anti-cytokeratin antibodies. Int J Biol Markers 1995; 10: 166–173.

9. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005; 59 (Suppl 2): S359–S362.

10. Feldstein AE, Wieckowska A, Lopez AR et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072–1078.

11. Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837–844.

12. Younossi ZM, Jarrar M, Nugent C et al. A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). Obes Surg 2008; 11: 1430–1437.

13. Zetterberg A, Skern T, Schoberl E et al. Molecular characterization of TPS (Abstract). 22nd Meeting. Groningen: ISOBM 1994: 354.

14. Bremer K, Eklund G, Björklund B. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res 1996; 16: 905–909.

15. Glimelius B, Hoffman K, Einarsson R et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996; 35: 141–148.

16. Klečka J, Pikner R, Toufarová P et al. Cytpkeratiny TPA, TPS, CYFRA 21-1 a UBC v séru a moči jako možné nádorové markery karcinomu močového měchýře. Ces Urol 2001; 1: 32–36.

17. http://www.cskb.cz/res/file/doporuceni/TM/TM_tab3.pdf.

18. Gonzalez-Quintela A, Abdulkader I, Campos J et al. Serum Levels of Keratin-18 Fragments (Tissue Polypeptide-Specific Antigen TPS) Are Correlated with Hepatocyte Apoptosis in Alcoholic Hepatitis. Dig Dis Sci 2009; 54: 648–653.

19. Gonzalez-Quintela A, Abdulkader I, Otero E et al. Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. Clin Chem Lab Med 2010; 48: 897–899.